← Eichor
Study identifier: NCT06752759 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Nebulized Ketamine for the Treatment of Major Depressive Disorder

Condition: Severe Depression · Moderate Depression · Ketamine  ·  Sponsor: Theresa Jacob, PhD, MPH

PhasePhase 3
Planned participants40
Who can joinAll sexes, 18 Years to 88 Years
Healthy volunteersNo

About this study

This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.

This description comes directly from the study's public registry record.

Talk to the study team

Jessica Poster, MD  ·  718-283-8170  ·  JPoster@maimo.org

Always discuss trial participation with your own doctor first.

Locations (1)

Maimonides Medical CenterBrooklyn, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06752759